Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uliledlimab - I-Mab Biopharma

Next Previous
Search
Drug Profile

Uliledlimab - I-Mab Biopharma

Alternative Names: Anti-CD73 monoclonal antibody- I-Mab Biopharma; TJ 004309; TJ-4309; TJD 5

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Developer I-MAB Biopharma; Shanghai Junshi Biosciences; TRACON Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Suspended Gastrointestinal cancer; Head and neck cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 06 Jan 2025 Suspended - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral)
  • 06 Jan 2025 Suspended - Phase-I/II for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral)
  • 06 Jan 2025 Suspended - Phase-II for Gastrointestinal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top